APOTEX-MYCOPHENOLATE mycophenolate mofetil 250 mg capsule blister pack

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

mycophenolate mofetil, Quantity: 250 mg

Commercializzato da:

Arrotex Pharmaceuticals Pty Ltd

INN (Nome Internazionale):

Mycophenolate mofetil

Forma farmaceutica:

Capsule

Composizione:

Excipient Ingredients: croscarmellose sodium; indigo carmine; Gelatin; titanium dioxide; purified water; iron oxide red; magnesium stearate; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Via di somministrazione:

Oral

Confezione:

100 capsules, 300 capsules

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Mycophenolate mofetil is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,Mycophenolate mofetil is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Dettagli prodotto:

Visual Identification: Opaque blue cap and opaque pink body in Size 1 capsule containing white to off white powder. "M250" and "APO" are imprinted on capsules in black ink.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2011-11-08